Get the Stockscreener App
4.41
5.76%
0.24
After Hours:
4.42
0.010
+0.23%
Precigen Inc stock is traded at $4.41, with a volume of 3.61M.
It is up +5.76% in the last 24 hours and up +19.51% over the past month.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
See More
Previous Close:
$4.17
Open:
$4.16
24h Volume:
3.61M
Relative Volume:
0.76
Market Cap:
$1.56B
Revenue:
$6.23M
Net Income/Loss:
$-95.90M
P/E Ratio:
-11.31
EPS:
-0.39
Net Cash Flow:
$-68.47M
1W Performance:
-9.07%
1M Performance:
+19.51%
6M Performance:
+126.15%
1Y Performance:
+306.45%
1-Day Range:
$4.10
$4.48
1-Week Range:
$3.93
$4.82
52-Week Range:
$1.0701
$5.225
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
4.41 | 1.48B | 6.23M | -95.90M | -68.47M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.53 | 115.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.14 | 79.76B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
799.33 | 50.16B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
366.86 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.75 | 38.85B | 4.98B | 69.59M | 525.67M | 0.5197 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Is PGEN’s PAPZIMEOS Exclusivity Quietly Redefining Its Competitive Moat in Rare Disease Therapy? - simplywall.st
Precigen reports strong adoption of RRP treatment PAPZIMEOS By Investing.com - Investing.com Nigeria
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Precigen (NASDAQ:PGEN) Trading Down 7.5%What's Next? - MarketBeat
New RRP treatment spreads nationwide as more insurers agree to cover it - Stock Titan
Iridian Asset Management LLC CT Sells 611,716 Shares of Precigen, Inc. $PGEN - MarketBeat
Is Precigen Inc. stock a buy on dipsInsider Buying & Technical Analysis for Trade Confirmation - ulpravda.ru
Precigen, Inc. (PGEN) Stock Analysis: Biotechnology Innovator With Potential 84% Upside - DirectorsTalk Interviews
Can Precigen Inc. stock beat market expectations this quarterJuly 2025 Review & Fast Moving Stock Trade Plans - ulpravda.ru
Can Precigen Inc. stock double in next 5 yearsMarket Weekly Review & Fast Exit and Entry Strategy Plans - ulpravda.ru
Precigen, Inc. (NASDAQ:PGEN): Are Analysts Optimistic? - simplywall.st
Market Sentiment Around Loss-Making Precigen, Inc. (NASDAQ:PGEN) - 富途牛牛
Is Precigen Inc. stock a buy before product launchesMorning Star Patterns & Start Small. End Wealthy. - ulpravda.ru
Will Precigen Inc. stock recover faster than peersGeopolitical Risk Analysis & Amplify Gains With Picks - ulpravda.ru
Will Precigen Inc. stock see insider buying2026 world cup usa national team quarterfinals star players possession football tactical prediction insights - ulpravda.ru
Precigen (NASDAQ:PGEN) Trading Down 6.1%What's Next? - MarketBeat
Precigen (NASDAQ:PGEN) Trading Down 4.2%Here's What Happened - MarketBeat
Will PGEN’s New Drug Make a Splash? - StocksToTrade
Precigen (NASDAQ:PGEN) Shares Up 5.1%What's Next? - MarketBeat
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday - Benzinga
Precigen (NASDAQ:PGEN) Advances Genetic Medicine Platforms - Kalkine Media
Precigen (NASDAQ:PGEN) Shares Gap Down Following Insider Selling - MarketBeat
Monday’s Insider Activity: Andreessen Horowitz Leads Major Buys - Investing.com
Monday’s Insider Activity: Andreessen Horowitz Leads Major Buys By Investing.com - Investing.com UK
Precigen Insider Sold Shares Worth $7,942,150, According to a Recent SEC Filing - marketscreener.com
Insider Selling: Precigen (NASDAQ:PGEN) Director Sells 1,900,036 Shares of Stock - MarketBeat
Kirk sells Precigen shares worth $7.9 million By Investing.com - Investing.com South Africa
Kirk sells Precigen shares worth $7.9 million - Investing.com
Precigen, Inc. (NASDAQ:PGEN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Profit Review: Will Precigen Inc. stock see insider buyingInsider Selling & Real-Time Buy Signal Alerts - Улправда
Market Outlook: Is Precigen Inc. stock a buy on dipsWeekly Profit Report & Real-Time Volume Analysis - ulpravda.ru
Precigen, Inc. (PGEN) Stock Analysis: Exploring a 103.84% Upside Potential in the Booming Biotech Sector - DirectorsTalk Interviews
Trade Alert: Independent Director Of Precigen Jeffrey Kindler Has Sold Stock - simplywall.st
PRECIGEN, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased - PR Newswire
Working capital per share of Precigen Inc – SWB:I5X - TradingView — Track All Markets
Precigen (PGEN) director reports sale of 235,467 shares of common stock on 12/12/2025 - Stock Titan
US High Growth Tech Stocks To Watch December 2025 - simplywall.st
Precigen Director Jeffrey B Kindler Sells 235,467 Shares - TradingView — Track All Markets
Spotlighting Bridgewater Bancshares And 2 Other Growth Stocks With Strong Insider Ownership - simplywall.st
Director’s Major Stock Sale Shakes Up Precigen! - TipRanks
Precigen Earnings Notes - Trefis
Precigen, Inc. (NASDAQ:PGEN) is definitely on the radar of institutional investors who own 31% of the company - Yahoo Finance
Dir Kindler Files To Sell 235,467 Of Precigen Inc [PGEN] - TradingView — Track All Markets
Precigen (NASDAQ:PGEN) Trading 5.3% HigherHere's What Happened - MarketBeat
Diametric Capital LP Buys New Holdings in Precigen, Inc. $PGEN - MarketBeat
Precigen Stock Up 280% in a Year — Is FDA Approval Behind This Big New Investor Bet? - sharewise.com
Patient Capital Management LLC Sells 1,103,560 Shares of Precigen, Inc. $PGEN - MarketBeat
Precigen (PGEN): Valuation in Focus After FDA Approval and Strengthened Cash Position - Sahm
Free cash flow per share of Precigen Inc – BX:I5X - TradingView
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.44%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):